Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Protein Kinase Inhibitors

Enzyme Inhibitors

Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years

Camrelizumab and Apatinib

Shiyue Li, MD

Ming Liu, MD

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients.

Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Subjects who meet the admission criteria will be treated with Camrelizumab and Apatinib until disease progression, intolerable toxicity, death, withdrawal of the patient or the researchers determined that the drug must be discontinued.

The primary end point of this study is safety of cryoablation combined with carillizumab and apatinib for MPLC. The secondary endpoints include objective response rate, disease control rate, time to progression, progression free survival and overall survival. Exploratory endpoint is to explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib.

About two to three weeks after cryoablation, Eligible patients sign informed consent and then begin treating with Camrelizumab and Apatinib.

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

An Exploratory Study on the Safety and Efficacy of Cryoablation Combined With Camrelizumab and Apatinib in the Treatment of Multiprimary Lung Cancer With Non-known Driving Genes

To explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib like PD-L1, ctDNA, CEA， CA125， CA153.

The occurrence of grade 3 to 5 adverse reactions was assessed by CTC AE v5.0

ShiYue Li

Deputy Director of Guangzhou Institute of Respiratory Disease

Gland and Hormone Related Diseases

Thyroid Neoplasms

Thyroid Diseases

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Antibodies

Immunoglobulins

Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.

All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment

Perform surgery if operable after neoadjuvant therapy

surgery

Perform core needle biopsy if inoperable after neoadjuvant therapy

core needle biopsy

Yu Wang, M.D.

Nai-si Huang, M.D.

To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study

Fudan University

Rare Diseases

Chordoma

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd

camrelizumab and apatinib

Zan Chen, Dr.

Zan Chen

Zan Chen, MD

This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and spread.

PRIMARY OBJECTIVES:

I. To assess the clinical benefit of the combination of Camrelizumab combined with Apatinib in patients with advanced chordomas by adverse events (AEs) and progression free survival (PFS).

SECONDARY OBJECTIVES:

I. Ascertain the safety of nivolumab in combination with relatlimab in subjects with metastatic or locally advanced/unresectable chordoma by the Overall survival (OS), objective response rate (MPR) and disease control rate (DCR)

EXPLORATORY OBJECTIVES:

I. Compare response rate (RR) and clinical benefit rate (CBR) in patients whose tumors are PD-L1+ and PD-L1- at baseline.

II. Compare RR and CBR in patients whose tumors are VEGFR+ and VEGFR- at baseline.

III. In the patients who are PD-L1 positive, compare RR and CBR in patients with 1% and 5% tumor membrane staining.

III. Determine the response to treatment based on the baseline mutation load. IV. Determine the ORR and CBR via Choi criteria.

OUTLINE:

To evaluate the safety and tolerability of carrilizol combined with apatinib in patients with recurrent, unresectable, chemotherapy-failed chordoma

After completion of study treatment, participants are followed up within 3 months.

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

A Single-arm Phase 2 Study of Apatinib (Anti-PD-1) Combined With Camrelizumab (Anti-VEGFR ) in Patients With Advanced Chordoma

To assess the clinical benefit of the combination of Camrelizumab combined with Apatinib in patients with advanced chordomas by adverse event and Progression-free survival.

To assess the clinical benefit of the combination of Camrelizumab combined with Apatinib in patients with advanced chordomas by Overall survival (OS).

To assess the clinical benefit of the combination of Camrelizumab combined with Apatinib in patients with advanced chordomas by objective response rate (OPR)

To assess the clinical benefit of the combination of Camrelizumab combined with Apatinib in patients with advanced chordomas by disease control rate (DCR).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer	NCT04201990	Lung Cancer	Camrelizumab an...	18 Years - 75 Years	Guangzhou Institute of Respiratory Disease
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer	NCT04612894	Thyroid Cancer	Camrelizumab an... surgery core needle bio...	14 Years -	Fudan University
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma	NCT06140732	Chordoma Chemotherapy Ef...	camrelizumab an...	18 Years -	Xuanwu Hospital, Beijing

Spots Global Cancer Trial Database for camrelizumab and apatinib